Excellent Cohort A Data From Final Primary Evaluation Period in Cynata GvHD Phase 1 Clinical Trial

- February 27th, 2018

Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP) is pleased to announce that the Primary Evaluation Period has been completed for the first cohort of patients in the clinical trial of its lead Cymerus™ mesenchymal stem cell product CYP-001, for the treatment of steroid-resistant graft versus host disease (GvHD). As quoted in … Continued

Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP) is pleased to announce that the Primary Evaluation Period has been completed for the first cohort of patients in the clinical trial of its lead Cymerus™ mesenchymal stem cell product CYP-001, for the treatment of steroid-resistant graft versus host disease (GvHD).

As quoted in the press release:

  • Efficacy data following completion of the Primary Evaluation Period (100 days) represents an improvement above the initial results announced in January

  • Overall survival at Day 100 was 87.5%

  • Overall Response rate by Day 100 was 100% (all eight participants showed an improvement in the severity of GvHD by at least one grade compared to baseline)
  • Complete Response rate by Day 100 was 50% (GvHD signs/symptoms completely resolved in four out of eight patients)
  • No treatment-related serious adverse events or safety concerns were identified during the Primary Evaluation Period

Click here to read the full press release.

The newest developments in genetics investing

 
Read our FREE outlook report on genetics investing

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply